Bio Green Med Solution, Inc. filings document the company's fire safety protection and distribution business, its completed shift from the former Cyclacel Pharmaceuticals biopharmaceutical operations, and its public-company governance. Regulatory reports include 8-K disclosures for quarterly and annual results, Regulation FD releases, material agreements, warrant exchanges, and preferred-stock dividend declarations.
The filing record also covers the company's common stock and 6% Convertible Exchangeable Preferred Stock, proxy materials for annual stockholder matters, Nasdaq listing-compliance matters involving the preferred stock, and corporate history items such as the acquisition of Fitters Sdn. Bhd., the liquidation of the former U.K. subsidiary, and the sale of Plogosertib.
Bio Green Med Solution, Inc. (BGMS) reported an insider transaction on Form 4. Director and Chief Financial Officer Kiu Cu Seng acquired 200,000 shares of common stock at $1.40 per share on 11/12/2025.
Following the transaction, the reporting person beneficially owned 200,000 shares, held in direct ownership. The filing was made by one reporting person.
Bio Green Med Solution (BGMS) reported an insider transaction on a Form 4: its Chief Executive Officer, who is also a Director and 10% Owner, acquired 300,178 shares of common stock at $1.4 on 11/12/2025.
Following this trade, the reporting person beneficially owns 1,111,131 shares, held directly. The filing notes share figures are adjusted for a 1-for-16 reverse stock split on May 12, 2025 and a 1-for-15 reverse stock split on July 7, 2025.
Bio Green Med Solution, Inc. (BGMS) reported third-quarter results and detailed its transition from biopharma to fire safety distribution following the September 12, 2025 acquisition of Malaysia-based Fitters Sdn. Bhd. BGMS recognized $81,000 in Q3 revenue, all from fire safety products, and posted a Q3 operating loss of $992,000 with a $988,000 net loss. For the nine months, revenue was $81,000 and net loss was $2.387 million.
Cash and cash equivalents were $3.838 million and total assets $8.158 million as of September 30, 2025. Stockholders’ equity improved to $7.096 million from a deficit at year-end 2024, aided by a $4.947 million gain on deconsolidation after its UK subsidiary entered liquidation. BGMS issued 699,158 shares (19.99%) as consideration for Fitters, recording $1.570 million of goodwill. The company also completed reverse stock splits (1-for-16 in May and 1-for-15 in July) and reported 3,497,537 common shares outstanding at quarter-end; 4,900,142 were outstanding as of November 11, 2025.
Management disclosed substantial doubt about the company’s ability to continue as a going concern, noting current cash is expected to fund operations into the first quarter of 2026. Subsequent to quarter-end, BGMS agreed to sell Plogosertib-related assets for $300,000 plus a potential $170,000 milestone.
Bio Green Med Solution, Inc. furnished a Form 8-K announcing it issued a press release with its third quarter 2025 results. The disclosure was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
The press release is attached as Exhibit 99.1 and dated November 13, 2025. The company’s securities are listed on the Nasdaq Capital Market under BGMS (common) and BGMSP (preferred).